Sept. 8, 2016 — The FDA’s Office of Prescription Drug Promotion (OPDP) takes issue with a conference panel for an unapproved cancer treatment in an Untitled Letter to Celator Pharmaceuticals Inc. issued Aug. 25. In the letter (CPX-351 Letter), OPDP states that a panel displayed at the June 2016 American Society for Clinical Oncology (ASCO) […]
Read more